Douglas J. Manion - Jan 1, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Pres and CEO, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jan 1, 2024
Transactions value $
-$9,581
Form type
4
Date filed
1/3/2024, 04:44 PM
Previous filing
Aug 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +27K +112.79% 50.9K Jan 1, 2024 Direct F1
transaction ACRS Common Stock Tax liability -$9.58K -9.13K -17.91% $1.05 41.8K Jan 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -27K -25% $0.00 81K Jan 1, 2024 Common Stock 27K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 On February 1, 2023, the Reporting Person was granted 108,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.